Bridgebio Oncology Therapeutics Inc (BBOT)

$12.29 +0.35 (2.93%)
Market Cap 945.61M
Revenue (ttm) 0.00
Net Income (ttm) -74.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 160,100
Avg Vol 277,182
Day's Range N/A - N/A
Shares Out 79.20M
Stochastic %K 80%
Beta 0.13
Analysts Strong Sell
Price Target $24.20

Company Profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 405 4770
Website: bbotx.com
Address:
256 E. Grand Avenue, Suite 104, South San Francisco, United States
Quantumup
Quantumup Nov. 3 at 11:43 AM
RBC Capital🏁 $RVMD Outperform/$77 $IMRX $BBOT $BBY $AMGN ERAS RBC Capital said in its initiation report: We believe RVMD is best positioned to execute on targeting RAS across oncology, given their impressive efficacy data, development lead, and focused pipeline. We think with a ph.Ill readout in 2026 highly likely to hit, a regulatory path significantly derisked by the recent CNPV, and a commercial opportunity of >$7B based on our checks with upwards of 50% intent to prescribe, we think shares are undervaluing the enthusiasm for daraxonrasib. While a certain amount of success is already priced in, and 1st gen KRAS inhibitor launches have been slow, we think RVMD's approach is likely to succeed and differentiate, and we would be buyers.
0 · Reply
Irish_lass
Irish_lass Oct. 30 at 10:50 PM
$BBOT https://investors.bbotx.com/news-releases/news-release-details/bbot-announces-poster-presentations-san-antonio-breast-cancer
0 · Reply
Skippy7
Skippy7 Oct. 30 at 6:48 PM
$BBIO I am surprised that more BBIO shareholders are not interested in $BBOT. Only 48 watchers. It is a spinoff from BBIO and BBIO remains a major stakeholder. I am curious of the impact on BBOT if BBIO is bought out. I own both.
1 · Reply
Irish_lass
Irish_lass Oct. 30 at 5:57 PM
$BBOT
0 · Reply
Irish_lass
Irish_lass Oct. 25 at 4:59 PM
$BBOT https://investors.bbotx.com/news-releases/news-release-details/preclinical-data-presented-2025-aacr-nci-eortc-international
0 · Reply
Quantumup
Quantumup Oct. 15 at 8:29 PM
Stifel $RVMD: We are resuming coverage of Revolution Medicines (RVMD) with a Buy rating and $85 target price. $IMRX $ERAS $DAWN $BBOT We believe RVMD is on the cusp of majorly disrupting the PDAC standard of care - we expect other indications to follow in years to come. The TAM is massive, ~30% of all solid tumors have some type of RAS alteration. RVMD's first-in-class pan-RAS is poised to benefit from a substantial first-to-market advantage; nearest competitors are years behind. We model first revenue for RVMD in 1Q27 and global revenue of $11.3B by 2035. Sector specialists are in 2 camps on RVMD: (1) too expensive, or (2) still undervalued for PDAC opportunity alone. We expect that once the 2L PDAC Ph3 reads out in 2026, the game changes as the stock becomes attractive to a more diverse group of investors, and those currently on the sideline would be wise to take a stake sooner.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 3 at 4:30 PM
$BBOT Current Stock Price: $12.29 No options data available.
0 · Reply
Irish_lass
Irish_lass Oct. 3 at 1:53 PM
$BBOT
0 · Reply
OGUZATA
OGUZATA Sep. 21 at 10:18 PM
$BBOT in all for tomorrow
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 19 at 10:52 AM
$BBOT trade update.
0 · Reply
Latest News on BBOT
BBOT to Participate in the Jefferies Global Healthcare Conference in London

Nov 3, 2025, 4:05 PM EST - 5 hours ago

BBOT to Participate in the Jefferies Global Healthcare Conference in London

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Oct 30, 2025, 5:45 PM EDT - 4 days ago

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

Oct 25, 2025, 12:30 PM EDT - 9 days ago

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 4:05 PM EDT - 11 days ago

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 21 days ago

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BBOT to Participate in Upcoming September Investor Healthcare Conferences

Aug 20, 2025, 8:00 AM EDT - 2 months ago

BBOT to Participate in Upcoming September Investor Healthcare Conferences

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

Aug 11, 2025, 4:30 PM EDT - 3 months ago

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

HLXB

Quantumup
Quantumup Nov. 3 at 11:43 AM
RBC Capital🏁 $RVMD Outperform/$77 $IMRX $BBOT $BBY $AMGN ERAS RBC Capital said in its initiation report: We believe RVMD is best positioned to execute on targeting RAS across oncology, given their impressive efficacy data, development lead, and focused pipeline. We think with a ph.Ill readout in 2026 highly likely to hit, a regulatory path significantly derisked by the recent CNPV, and a commercial opportunity of >$7B based on our checks with upwards of 50% intent to prescribe, we think shares are undervaluing the enthusiasm for daraxonrasib. While a certain amount of success is already priced in, and 1st gen KRAS inhibitor launches have been slow, we think RVMD's approach is likely to succeed and differentiate, and we would be buyers.
0 · Reply
Irish_lass
Irish_lass Oct. 30 at 10:50 PM
$BBOT https://investors.bbotx.com/news-releases/news-release-details/bbot-announces-poster-presentations-san-antonio-breast-cancer
0 · Reply
Skippy7
Skippy7 Oct. 30 at 6:48 PM
$BBIO I am surprised that more BBIO shareholders are not interested in $BBOT. Only 48 watchers. It is a spinoff from BBIO and BBIO remains a major stakeholder. I am curious of the impact on BBOT if BBIO is bought out. I own both.
1 · Reply
Irish_lass
Irish_lass Oct. 30 at 5:57 PM
$BBOT
0 · Reply
Irish_lass
Irish_lass Oct. 25 at 4:59 PM
$BBOT https://investors.bbotx.com/news-releases/news-release-details/preclinical-data-presented-2025-aacr-nci-eortc-international
0 · Reply
Quantumup
Quantumup Oct. 15 at 8:29 PM
Stifel $RVMD: We are resuming coverage of Revolution Medicines (RVMD) with a Buy rating and $85 target price. $IMRX $ERAS $DAWN $BBOT We believe RVMD is on the cusp of majorly disrupting the PDAC standard of care - we expect other indications to follow in years to come. The TAM is massive, ~30% of all solid tumors have some type of RAS alteration. RVMD's first-in-class pan-RAS is poised to benefit from a substantial first-to-market advantage; nearest competitors are years behind. We model first revenue for RVMD in 1Q27 and global revenue of $11.3B by 2035. Sector specialists are in 2 camps on RVMD: (1) too expensive, or (2) still undervalued for PDAC opportunity alone. We expect that once the 2L PDAC Ph3 reads out in 2026, the game changes as the stock becomes attractive to a more diverse group of investors, and those currently on the sideline would be wise to take a stake sooner.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 3 at 4:30 PM
$BBOT Current Stock Price: $12.29 No options data available.
0 · Reply
Irish_lass
Irish_lass Oct. 3 at 1:53 PM
$BBOT
0 · Reply
OGUZATA
OGUZATA Sep. 21 at 10:18 PM
$BBOT in all for tomorrow
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 19 at 10:52 AM
$BBOT trade update.
0 · Reply
Irish_lass
Irish_lass Sep. 18 at 3:29 PM
$BBOT
0 · Reply
_www_larval_com_
_www_larval_com_ Sep. 17 at 7:57 PM
$FTHM 7%[0%] $TGE -7%[10%] $HIND 6%[8%] $LHAI 6%[10%] $BBOT -4%[9%] most notable movement into the final minutes of trading.
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 12:30 PM
Leerink Partners has updated their rating for BridgeBio Oncology ( $BBOT ) to Outperform with a price target of 25.
0 · Reply
JarvisFlow
JarvisFlow Sep. 15 at 12:00 PM
HC Wainwright & Co. has updated their rating for BridgeBio Oncology ( $BBOT ) to Buy with a price target of 27.
0 · Reply
Quantumup
Quantumup Sep. 15 at 11:31 AM
H.C. Wainwright🏁 $BBOT Buy-$27 and said, We are initiating coverage of BridgeBio Oncology Therapeutics ( $BBOT), a spin-out of BridgeBio Pharma ( $BBIO; Buy; Selvaraju), with a Buy rating and 12-month price target of $27 per share. $BBOT is a clinical-stage biotechnology company developing next-generation inhibitors that are designed to provide cancer patients with significant benefit over standard-of-care treatments. H.C. Wainwright went on to say:
0 · Reply
StockScanners
StockScanners Sep. 9 at 4:06 AM
$BBOT keep watch if this holds above 10.35
0 · Reply
Irish_lass
Irish_lass Sep. 8 at 5:23 PM
$BBOT 👀
0 · Reply
Irish_lass
Irish_lass Sep. 8 at 4:46 PM
$BBOT Morgan Stanley Conference https://event.webcasts.com/viewer/event.jsp?ei=1734301&tp_key=74dcd75ba4
0 · Reply
garygb
garygb Sep. 7 at 5:03 PM
$BBOT Got upgraded.
0 · Reply
Irish_lass
Irish_lass Sep. 5 at 4:57 PM
$BBOT https://investors.bbotx.com/events/event-details/morgan-stanley-global-healthcare-conference
0 · Reply
Quantumup
Quantumup Sep. 5 at 10:58 AM
Truist🏁 $RVMD Buy/$99. $BBOT $DAWN $ERAS $BMY Truist said in its initiation report: Revolution Medicines (RevMed, $RVMD) has gone big in targeting one of the biggest drivers of cancer (RAS) where mutations drive one-third of all new cancer diagnoses. The company has built the broadest pipeline attacking these targets - most of them first-in-class - including a coveted multi-target "pan" inhibitor (Daraxonrasib), which we project to be a $8B+ drug, and will accelerate faster than implied by consensus. We think the current share price is missing the revolutionary potential of $RVMD's drugs when used in combinations, but we believe these features will gain appreciation in the next 12-18 months as new data emerges. We rate $RVMD a Buy, with a $99 PT.
0 · Reply
JarvisFlow
JarvisFlow Sep. 4 at 1:00 PM
Oppenheimer updates rating for BridgeBio Oncology ( $BBOT ) to Outperform, target set at 23.
0 · Reply